Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T21945
|
||||
Former ID |
TTDC00304
|
||||
Target Name |
Sodium-dependent noradrenaline transporter
|
||||
Gene Name |
SLC6A2
|
||||
Synonyms |
NET; Norepinephrine transporter; SLC6A2
|
||||
Target Type |
Successful
|
||||
Disease | Attention deficit hyperactivity disorder; Depression; Cocaine addiction [ICD9: 303-304, 304.2, 311, 314.00, 314.01; ICD10: F10-F19, F14.2, F32, F90] | ||||
Attention deficit hyperactivity disorder [ICD9: 314; ICD10: F90] | |||||
Attention deficit hyperactivity disorder; Severe mood disorders [ICD9: 296, 314.00, 314.01; ICD10: F30-F39, F90] | |||||
Anesthesia; Ocular disease [ICD9:338; ICD10: R20.0, H00-H59] | |||||
Cancer pain [ICD9: 140-229, 338,780; ICD10: R52, G89] | |||||
Chronic low back pain; Neuropathic pain [ICD9: 338, 356.0, 356.8, 724.2, 724.5,780; ICD10: G64, G90.0, M54, M54.5, R52, G89] | |||||
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3] | |||||
Depression; Attention deficit hyperactivity disorder [ICD9: 311, 314.00, 314.01; ICD10: F30-F39, F90] | |||||
Depression [ICD9: 311; ICD10: F30-F39] | |||||
Depression; Bipolar disorder [ICD9:311, 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10: F30-F39, F31, F40-F42] | |||||
Depression; Chronic pain [ICD9: 311, 338,780; ICD10: F30-F39, R52, G89] | |||||
Depression; Attention deficit hyperactivity disorder [ICD9:311, 314; ICD10: F30-F39, F90] | |||||
Depression; Anxiety disorder [ICD9:311, 300; ICD10: F30-F39, F32, F40-F42] | |||||
Fatigue [ICD10: R53] | |||||
Fibromyalgia [ICD9: 729.1; ICD10: M79.7] | |||||
Glaucoma [ICD9: 365; ICD10: H40-H42] | |||||
Heart failure diagnosis [ICD9: 428; ICD10: I50] | |||||
Heart failure [ICD9: 428; ICD10: I50] | |||||
Moderate-to-severe acute pain [ICD9: 338,780; ICD10: R52, G89] | |||||
Mood disorder [ICD10: F30-F39] | |||||
Migraine; Obisity [ICD9: 278, 346; ICD10: E66, G43] | |||||
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10: F32, F33, M32] | |||||
Neuroendocrine cancer [ICD10: C7A] | |||||
Neuroblastoma [ICD9: 194.0, 194.5, 194.6, 227.0, 227.5, 227.6, 237.3, 255.6; ICD10: C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7] | |||||
Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10: I21, I22, R52, R52.1-R52.2, R60.9, G89] | |||||
Neuropathic pain [ICD9: 356.0, 356.8; ICD10: G64, G90.0] | |||||
Obesity [ICD9: 278; ICD10: E66] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
Smoking cessation [ICD9: 292; ICD10: F17.2] | |||||
Severe mood disorders [ICD9: 296; ICD10: F30-F39] | |||||
Unspecified [ICD code not available] | |||||
Function |
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
|
||||
BioChemical Class |
Neurotransmitter:sodium symporter
|
||||
Target Validation |
T21945
|
||||
UniProt ID | |||||
Sequence |
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL VAQRDIRQFQLQHWLAI |
||||
Drugs and Mode of Action | |||||
Drug(s) | Amfepramone | Drug Info | Approved | Obesity | [536103] |
Amitriptyline | Drug Info | Approved | Depression; Chronic pain | [536306], [539289], [551871] | |
Amoxapine | Drug Info | Approved | Major depressive disorder | [538247], [539292], [551871] | |
Atomoxetine | Drug Info | Approved | Attention deficit hyperactivity disorder | [536661], [542125] | |
Bupropion | Drug Info | Approved | Smoking cessation | [551871] | |
Cocaine | Drug Info | Approved | Anesthesia; Ocular disease | [539436], [550681], [551871] | |
Desipramine | Drug Info | Approved | Depression; Attention deficit hyperactivity disorder | [536306], [539526], [551871] | |
Desvenalfaxine succinate | Drug Info | Approved | Fibromyalgia | [536647] | |
Diethylpropion | Drug Info | Approved | Migraine; Obisity | [536661], [542170] | |
Duloxetine | Drug Info | Approved | Depression | [536306], [539298] | |
Imipramine | Drug Info | Approved | Depression; Anxiety disorder | [536306], [540475], [551871] | |
Iobenguane I 123 injection | Drug Info | Approved | Heart failure diagnosis | [524423], [551871] | |
Iobenguane I-123 | Drug Info | Approved | Neuroendocrine cancer | [529941] | |
Iobenguane I-123 - GE Healthcare | Drug Info | Approved | Unspecified | [551871] | |
Levomilnacipran | Drug Info | Approved | Fibromyalgia | [530677], [542458] | |
Maprotiline | Drug Info | Approved | Major depressive disorder | [551871] | |
Mazindol | Drug Info | Approved | Obesity | [468026], [535114] | |
Milnacipran | Drug Info | Approved | Depression | [536580], [542459] | |
Phenmetrazine | Drug Info | Approved | Obesity | [550743] | |
Phentermine | Drug Info | Approved | Obesity | [536710], [542288] | |
Protriptyline | Drug Info | Approved | Depression; Bipolar disorder | [536306], [542305], [551871] | |
Reboxetine | Drug Info | Approved | Depression | [468039], [536306] | |
Sibutramine | Drug Info | Approved | Obesity | [536710], [539665] | |
Tapentadol hydrochloride | Drug Info | Approved | Moderate-to-severe acute pain | [529941] | |
Trimipramine | Drug Info | Approved | Major depressive disorder | [551871] | |
Ultracet | Drug Info | Approved | Pain | [536242] | |
Venlafaxine | Drug Info | Approved | Depression | [537533], [542345] | |
Hypericum | Drug Info | Phase 4 | Discovery agent | [522154] | |
Amitifadine | Drug Info | Phase 3 | Obesity | [527289], [528424] | |
Bicifadine | Drug Info | Phase 3 | Chronic low back pain; Neuropathic pain | [536374] | |
Bupropion+naltrexone | Drug Info | Phase 3 | Obesity | [532233] | |
Dasotraline | Drug Info | Phase 3 | Mood disorder | [524969], [543060] | |
Roclatan | Drug Info | Phase 3 | Glaucoma | [525325] | |
Suronacrine maleate | Drug Info | Phase 3 | Cognitive disorders | [551848] | |
18F-LMI-1195 | Drug Info | Phase 2 | Heart failure | [522972] | |
DOV 21947 | Drug Info | Phase 2 | Severe mood disorders | [536580] | |
MCT-125 | Drug Info | Phase 2 | Fatigue | [548187] | |
Metaiodobenzylguanidine I-131 | Drug Info | Phase 2 | Neuroblastoma | [545811] | |
METHYLENEDIOXYMETHAMPHETAMINE | Drug Info | Phase 2 | Discovery agent | [521857] | |
Rhopressa | Drug Info | Phase 2 | Glaucoma | [533091] | |
TD-9855 | Drug Info | Phase 2 | Pain | [533083] | |
XEN-2174 | Drug Info | Phase 2 | Cancer pain | [548033] | |
BL-1021 | Drug Info | Phase 1 | Pain | [523040] | |
GSK-1360707 | Drug Info | Phase 1 | Major depressive disorder | [523095] | |
DOV-216303 | Drug Info | Discontinued in Phase 2 | Severe mood disorders | [536580] | |
Esreboxetine | Drug Info | Discontinued in Phase 2 | Fibromyalgia | [549540] | |
GSK372475 | Drug Info | Discontinued in Phase 2 | Attention deficit hyperactivity disorder; Severe mood disorders | [533085] | |
Manifaxine | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [546210] | |
Napitane mesilate | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [545865] | |
NS 2359 | Drug Info | Discontinued in Phase 2 | Attention deficit hyperactivity disorder; Depression; Cocaine addiction | [536580] | |
NS-2389 | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [546575] | |
R-sibutramine metabolite | Drug Info | Discontinued in Phase 2 | Depression; Attention deficit hyperactivity disorder | [536580] | |
Radafaxine | Drug Info | Discontinued in Phase 2 | Major depressive disorder | [536295] | |
SPD-473 | Drug Info | Discontinued in Phase 2 | Mood disorder | [546832] | |
NSD-644 | Drug Info | Discontinued in Phase 1 | Neurological disease | [548670] | |
Radaxafine HCl | Drug Info | Discontinued in Phase 1 | Neuropathic pain | [536374] | |
RG-7166 | Drug Info | Discontinued in Phase 1 | Major depressive disorder | [549027] | |
Inhibitor | ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine | Drug Info | [529620] | ||
(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine | Drug Info | [530012] | |||
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol | Drug Info | [530946] | |||
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol | Drug Info | [530946] | |||
(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol | Drug Info | [527968] | |||
(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol | Drug Info | [530918] | |||
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine | Drug Info | [530012] | |||
(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile | Drug Info | [530012] | |||
(R)-DULOXETINE | Drug Info | [530368] | |||
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide | Drug Info | [530367] | |||
(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide | Drug Info | [530367] | |||
(R)-Norfluoxetine | Drug Info | [529814] | |||
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine | Drug Info | [530012] | |||
(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile | Drug Info | [530012] | |||
(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide | Drug Info | [530367] | |||
(S)-NORDULOXETINE | Drug Info | [530368] | |||
(S)-Norfluoxetine | Drug Info | [529814] | |||
1-(1,2-diphenylethyl)piperazine | Drug Info | [528224] | |||
1-(1,4-diphenylbutan-2-yl)piperazine | Drug Info | [528226] | |||
1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) | Drug Info | [530918] | |||
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) | Drug Info | [530918] | |||
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine | Drug Info | [530918] | |||
1-(1-phenyl-2-o-tolylethyl)piperazine | Drug Info | [528224] | |||
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine | Drug Info | [533479] | |||
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine | Drug Info | [530474] | |||
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) | Drug Info | [530918] | |||
1-(2-(2-bromophenyl)-1-phenylethyl)piperazine | Drug Info | [528224] | |||
1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine | Drug Info | [530596] | |||
1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine | Drug Info | [528224] | |||
1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine | Drug Info | [528224] | |||
1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine | Drug Info | [528224] | |||
1-(2-(2-fluorobenzyloxy)phenyl)piperazine | Drug Info | [530474] | |||
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine | Drug Info | [530918] | |||
1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine | Drug Info | [528224] | |||
1-(2-(3-fluorophenoxy)phenyl)piperazine | Drug Info | [530474] | |||
1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine | Drug Info | [528224] | |||
1-(2-(4-fluorophenoxy)phenyl)piperazine | Drug Info | [530474] | |||
1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine | Drug Info | [530012] | |||
1-(2-(benzyloxy)phenyl)piperazine | Drug Info | [530474] | |||
1-(2-(phenoxymethyl)phenyl)piperazine | Drug Info | [530474] | |||
1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-(2-phenoxyphenyl)piperazine | Drug Info | [530474] | |||
1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol | Drug Info | [527062] | |||
1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol | Drug Info | [527062] | |||
1-(3,4-dichlorophenyl)-3-aza-bicyclo[3.1.0]hexane | Drug Info | [531114] | |||
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one | Drug Info | [530728] | |||
1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one | Drug Info | [530728] | |||
1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one | Drug Info | [530728] | |||
1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one | Drug Info | [530728] | |||
1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one | Drug Info | [528036] | |||
1S,2R-milnacipran | Drug Info | [529776] | |||
2-((2-iodophenoxy)(phenyl)methyl)morpholine | Drug Info | [528517] | |||
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine | Drug Info | [528517] | |||
2-(2'-Aminoethyl)-5-benzyltetrahydrofuran | Drug Info | [529955] | |||
2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine | Drug Info | [533479] | |||
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine | Drug Info | [530596] | |||
2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine | Drug Info | [530596] | |||
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine | Drug Info | [530596] | |||
2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile | Drug Info | [528224] | |||
2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran | Drug Info | [529955] | |||
2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran | Drug Info | [529955] | |||
2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran | Drug Info | [529955] | |||
2-(Aminomethyl)-5-phenethyltetrahydrofuran | Drug Info | [529955] | |||
2-(N,N-Diethylamino)-3'-chloropropiophenone | Drug Info | [530442] | |||
2-(N-Cyclopentylamino)-3'-bromopropiophenone | Drug Info | [530728] | |||
2-(N-Cyclopentylamino)-3'-chloropropiophenone | Drug Info | [530442] | |||
2-(N-Cyclopentylamino)-3'-fluoropropiophenone | Drug Info | [530728] | |||
2-(N-Cyclopentylamino)-3'-methoxypropiophenone | Drug Info | [530728] | |||
2-(N-Cyclopentylamino)-3'-methylpropiophenone | Drug Info | [530728] | |||
2-(N-Cyclopropylamino)-3-chloropropiophenone | Drug Info | [530442] | |||
2-(N-Pyrrolidinyl)-3'-bromopropiophenone | Drug Info | [530728] | |||
2-(N-Pyrrolidinyl)-3'-fluoropropiophenone | Drug Info | [530728] | |||
2-(N-Pyrrolidinyl)-3'-methoxypropiophenone | Drug Info | [530728] | |||
2-(N-Pyrrolidinyl)-3'-methylpropiophenone | Drug Info | [530728] | |||
2-(N-Pyrrolidinyl)-3'-nitropropiophenone | Drug Info | [530728] | |||
2-(N-tert-Butylamino)-3',4'-dichloropropiophenone | Drug Info | [530442] | |||
2-(N-tert-Butylamino)-3'-chloroheptanophenone | Drug Info | [530442] | |||
2-(N-tert-Butylamino)-3'-chlorohexanophenone | Drug Info | [530442] | |||
2-(N-tert-Butylamino)-3'-chlorooctanophenone | Drug Info | [530442] | |||
2-(N-tert-Butylamino)-3'-chloropentanophenone | Drug Info | [530442] | |||
2-(N-tert-Butylamino)propiophenone | Drug Info | [530442] | |||
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one | Drug Info | [530728] | |||
2-(tert-butylamino)-1-m-tolylpropan-1-one | Drug Info | [530728] | |||
2-(tert-butylamino)-1-p-tolylpropan-1-one | Drug Info | [530728] | |||
2-(tert-Butylamino)-3',4'-dichlorobutyrophenone | Drug Info | [530442] | |||
2-(tert-Butylamino)-3',4'-dichloropentanophenone | Drug Info | [530442] | |||
2-Amino-1-(4-methylthiophenyl)propane | Drug Info | [530347] | |||
2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran | Drug Info | [529955] | |||
2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran | Drug Info | [529955] | |||
2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran | Drug Info | [529955] | |||
2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran | Drug Info | [529955] | |||
2-Aminomethyl-5-(phenyl)tetrahydrofuran | Drug Info | [529955] | |||
2-phenoxy-3-(piperidin-4-yl)pyridine | Drug Info | [530596] | |||
2pyrrolidin-1-yl-1-phenylpentan-1-one | Drug Info | [528036] | |||
3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine | Drug Info | [529764] | |||
3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile | Drug Info | [528224] | |||
3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol | Drug Info | [528224] | |||
3-(3'-furyl)-aniline | Drug Info | [528735] | |||
3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine | Drug Info | [530596] | |||
3-p-Tolyl-8-aza-bicyclo[3.2.1]octane | Drug Info | [525906] | |||
3alpha-(bis-chloro-phenylmethoxy)tropane | Drug Info | [528473] | |||
4-((naphthalen-2-yloxy)methyl)piperidine | Drug Info | [530012] | |||
4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine | Drug Info | [528760] | |||
4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(2-fluorobenzyloxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(3-chlorophenoxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine | Drug Info | [530474] | |||
4-(2-(3-fluorophenoxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(4-fluorobenzyloxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine | Drug Info | [530474] | |||
4-(2-(4-fluorophenoxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(benzyloxy)-3-fluorophenyl)piperidine | Drug Info | [530474] | |||
4-(2-(benzyloxy)-6-fluorophenyl)piperidine | Drug Info | [530474] | |||
4-(2-(benzyloxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-(phenoxymethyl)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine | Drug Info | [530596] | |||
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine | Drug Info | [530474] | |||
4-(2-fluoro-6-phenoxyphenyl)piperidine | Drug Info | [530474] | |||
4-(2-phenoxyphenyl)piperidine | Drug Info | [530474] | |||
4-(3'-furyl)-aniline | Drug Info | [528735] | |||
4-(3-fluoro-2-phenoxyphenyl)piperidine | Drug Info | [530474] | |||
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | [531079] | |||
6-(piperidin-4-ylmethoxy)-2-naphthonitrile | Drug Info | [530012] | |||
7-(piperidin-4-ylmethoxy)-2-naphthonitrile | Drug Info | [530012] | |||
8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane | Drug Info | [525906] | |||
Amfepramone | Drug Info | [536103] | |||
AMIFLAMINE | Drug Info | [533479] | |||
Amitifadine | Drug Info | [543974] | |||
Amitriptyline | Drug Info | [536774], [537983] | |||
Amoxapine | Drug Info | [537875] | |||
Atomoxetine | Drug Info | [536025], [536749] | |||
Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine | Drug Info | [529592] | |||
Bupropion | Drug Info | [537422] | |||
Bupropion+naltrexone | Drug Info | [536710] | |||
Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine | Drug Info | [529530] | |||
Cocaine | Drug Info | [537241] | |||
D-166A | Drug Info | [529287] | |||
D-211A | Drug Info | [529287] | |||
D-211B | Drug Info | [529287] | |||
D-254C | Drug Info | [529287] | |||
D-257A | Drug Info | [529287] | |||
D-257C | Drug Info | [529287] | |||
Dasotraline | Drug Info | [533235] | |||
Desipramine | Drug Info | [537457] | |||
Desvenalfaxine succinate | Drug Info | [536647] | |||
Diethylpropion | Drug Info | [536130] | |||
DIFLUOROBENZTROPINE | Drug Info | [528473] | |||
DOV 21947 | Drug Info | [536580] | |||
DOV-216303 | Drug Info | [536580] | |||
Duloxetine | Drug Info | [536331], [537531] | |||
GSK-1360707 | Drug Info | [532361] | |||
GSK372475 | Drug Info | [536580] | |||
Hypericum | Drug Info | [534900] | |||
Imipramine | Drug Info | [534848], [536967] | |||
Iobenguane I 123 injection | Drug Info | [529941] | |||
Iobenguane I-123 | Drug Info | [543974] | |||
Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine | Drug Info | [528048] | |||
KF-A5 | Drug Info | [529032] | |||
Maprotiline | Drug Info | [536083] | |||
MCT-125 | Drug Info | [543974] | |||
MDL-28618 | Drug Info | [529620] | |||
METHYLENEDIOXYAMPHETAMINE | Drug Info | [530914] | |||
METHYLENEDIOXYMETHAMPHETAMINE | Drug Info | [530347] | |||
Milnacipran | Drug Info | [537622] | |||
N,N-dimethyl(2-phenoxyphenyl)methanamine | Drug Info | [529278] | |||
N-(2-oxazolemethyl)milnacipran | Drug Info | [529263] | |||
N-benzyl-N-isobutylpiperidin-4-amine | Drug Info | [528048] | |||
N-desalkylquetiapine | Drug Info | [529198] | |||
NISOXETINE | Drug Info | [529670] | |||
norzotepine | Drug Info | [530783] | |||
NS 2359 | Drug Info | [536499] | |||
Para-chloroamphetamine | Drug Info | [530347] | |||
PF-18298 | Drug Info | [530918] | |||
PF-3409409 | Drug Info | [530265] | |||
PF-526014 | Drug Info | [530918] | |||
Phenmetrazine | Drug Info | [535503] | |||
Phentermine | Drug Info | [535068] | |||
POLYGALATENOSIDE B | Drug Info | [528443] | |||
Protriptyline | Drug Info | [537742] | |||
PTI-601 | Drug Info | [543974] | |||
PYROVALERONE | Drug Info | [528036] | |||
R-NORDULOXETINE | Drug Info | [530368] | |||
Radafaxine | Drug Info | [536122], [536295] | |||
Radaxafine HCl | Drug Info | [536374] | |||
Reboxetine | Drug Info | [535127] | |||
RG-7166 | Drug Info | [549028] | |||
RTI-219 | Drug Info | [528932] | |||
S-34324 | Drug Info | [527481] | |||
S33005 | Drug Info | [536286] | |||
SPD-473 | Drug Info | [527287] | |||
Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine | Drug Info | [529530] | |||
Trimipramine | Drug Info | [536168] | |||
Ultracet | Drug Info | [537457] | |||
Venlafaxine | Drug Info | [537422] | |||
WAY-256805 | Drug Info | [529536] | |||
WIN-35065-2 | Drug Info | [534240] | |||
WIN-35066-2 | Drug Info | [527309] | |||
WIN_35428 | Drug Info | [534240] | |||
XEN-2174 | Drug Info | [527387] | |||
[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine | Drug Info | [527062] | |||
[3H]mazindol | Drug Info | [527164] | |||
[3H]nisoxetine | Drug Info | [543974] | |||
{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine | Drug Info | [530455] | |||
Enhancer | 18F-LMI-1195 | Drug Info | [532351] | ||
Modulator | 3,4-Methylenedioxymethamphetamine | Drug Info | [551382] | ||
Bicifadine | Drug Info | ||||
BL-1021 | Drug Info | ||||
Iobenguane I-123 - GE Healthcare | Drug Info | [529941] | |||
Levomilnacipran | Drug Info | [530677] | |||
Manifaxine | Drug Info | [527845] | |||
Mazindol | Drug Info | [556264] | |||
Metaiodobenzylguanidine I-131 | Drug Info | [532685] | |||
MMDA | Drug Info | [551393] | |||
Napitane mesilate | Drug Info | ||||
NS-2389 | Drug Info | [550007] | |||
R-sibutramine metabolite | Drug Info | ||||
Rhopressa | Drug Info | [533091] | |||
Roclatan | Drug Info | [1572591] | |||
Sibutramine | Drug Info | [556264] | |||
Suronacrine maleate | Drug Info | ||||
Tapentadol hydrochloride | Drug Info | [529941] | |||
TD-9855 | Drug Info | [533083] | |||
Blocker | Esreboxetine | Drug Info | [549974] | ||
Activator | NSD-644 | Drug Info | [551423] | ||
Agonist | TQ-1017 | Drug Info | [551871] | ||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
References | |||||
Ref 468026 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4797). | ||||
Ref 468039 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4808). | ||||
Ref 521857 | ClinicalTrials.gov (NCT00353938) Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder. U.S. National Institutes of Health. | ||||
Ref 522154 | ClinicalTrials.gov (NCT00557427) Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression. U.S. National Institutes of Health. | ||||
Ref 522972 | ClinicalTrials.gov (NCT01085175) Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing. U.S. National Institutes of Health. | ||||
Ref 523040 | ClinicalTrials.gov (NCT01121380) A Study Intended to Evaluate Safety, Tolerability and Pharmacokinetics (PK) Parameters of BL-1021. U.S. National Institutes of Health. | ||||
Ref 523095 | ClinicalTrials.gov (NCT01153802) An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Dosesof GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands. U.S. National Institutes of Health. | ||||
Ref 524423 | ClinicalTrials.gov (NCT01936649) Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.. U.S. National Institutes of Health. | ||||
Ref 524969 | ClinicalTrials.gov (NCT02276209) Dasotraline Adult ADHD Study. U.S. National Institutes of Health. | ||||
Ref 525325 | ClinicalTrials.gov (NCT02558400) Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension. | ||||
Ref 527289 | J Clin Pharmacol. 2004 Dec;44(12):1360-7.DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. | ||||
Ref 528424 | Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor. CNS Drug Rev. 2006 Summer;12(2):123-34. | ||||
Ref 532233 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43. | ||||
Ref 533083 | Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. | ||||
Ref 533085 | Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder. Drug Des Devel Ther. 2014 Dec 1;8:2321-32. | ||||
Ref 533091 | Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. | ||||
Ref 535114 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000 Oct;13(2):193-9. | ||||
Ref 536242 | The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis. 2006;25(2):53-8. | ||||
Ref 536580 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
Ref 536661 | Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. Epub 2008 Mar 18. | ||||
Ref 537533 | Desvenlafaxine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2009;5:127-36. Epub 2009 Apr 8. | ||||
Ref 538247 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072688. | ||||
Ref 539289 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 200). | ||||
Ref 539292 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 201). | ||||
Ref 539298 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 202). | ||||
Ref 539436 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2286). | ||||
Ref 539526 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2399). | ||||
Ref 539665 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2586). | ||||
Ref 540475 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 357). | ||||
Ref 542125 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7118). | ||||
Ref 542170 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7161). | ||||
Ref 542288 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7269). | ||||
Ref 542305 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7285). | ||||
Ref 542345 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7321). | ||||
Ref 542458 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7435). | ||||
Ref 542459 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7436). | ||||
Ref 543060 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8308). | ||||
Ref 545811 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004852) | ||||
Ref 545865 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005107) | ||||
Ref 546210 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006906) | ||||
Ref 546575 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009012) | ||||
Ref 546832 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010517) | ||||
Ref 548033 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021315) | ||||
Ref 548187 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022855) | ||||
Ref 548670 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571) | ||||
Ref 549027 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) | ||||
Ref 525906 | Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. | ||||
Ref 527062 | J Med Chem. 2004 May 6;47(10):2624-34.Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. | ||||
Ref 527164 | Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. Epub 2004 Jul 22. | ||||
Ref 527287 | Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31. Epub 2004 Nov 12. | ||||
Ref 527309 | J Med Chem. 2004 Dec 2;47(25):6401-9.Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl ester isomers. | ||||
Ref 527387 | Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6. | ||||
Ref 527481 | J Med Chem. 2005 Mar 24;48(6):2054-71.Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity. | ||||
Ref 527845 | Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9. | ||||
Ref 527968 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5. Epub 2006 Jan 18.Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. | ||||
Ref 528036 | J Med Chem. 2006 Feb 23;49(4):1420-32.1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. | ||||
Ref 528048 | Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8. Epub 2006 Feb 23.N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. | ||||
Ref 528224 | Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. Epub 2006 Jun 5.N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. | ||||
Ref 528226 | Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. Epub 2006 Jun 5.Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. | ||||
Ref 528443 | J Nat Prod. 2006 Sep;69(9):1305-9.Antidepressant principles of the roots of Polygala tenuifolia. | ||||
Ref 528473 | J Med Chem. 2006 Oct 19;49(21):6391-9.Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation. | ||||
Ref 528517 | Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. Epub 2006 Oct 12.Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. | ||||
Ref 528735 | J Med Chem. 2007 Apr 19;50(8):1925-32. Epub 2007 Mar 17.Designing active template molecules by combining computational de novo design and human chemist's expertise. | ||||
Ref 528760 | Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104. Epub 2007 Mar 16.Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. | ||||
Ref 528932 | J Med Chem. 2007 Jul 26;50(15):3686-95. Epub 2007 Jun 30.Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2beta-[5-(substituted phenyl)thiazol-2-yl]tropanes. | ||||
Ref 529032 | Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. Epub 2007 Sep 10.Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. | ||||
Ref 529198 | N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008 Sep;33(10):2303-12. Epub 2007 Dec 5. | ||||
Ref 529263 | Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. Epub 2008 Jan 9.Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. | ||||
Ref 529278 | Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. | ||||
Ref 529287 | Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. Epub 2008 Jan 11.Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters. | ||||
Ref 529530 | Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. Epub 2008 May 20.Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). | ||||
Ref 529536 | J Med Chem. 2008 Jul 10;51(13):4038-49. Epub 2008 Jun 17.Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. | ||||
Ref 529592 | Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. Epub 2008 Jun 25.Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity. | ||||
Ref 529620 | Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8. Epub 2008 Jul 17.Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. | ||||
Ref 529670 | Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31. Epub 2008 Aug 22.Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. | ||||
Ref 529764 | Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70. Epub 2008 Oct 11.Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. | ||||
Ref 529776 | J Med Chem. 2008 Nov 27;51(22):7265-72.Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. | ||||
Ref 529814 | Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. | ||||
Ref 529955 | Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. Epub 2009 Jan 15.2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. | ||||
Ref 530012 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. | ||||
Ref 530265 | Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. Epub 2009 Jul 2.Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template. | ||||
Ref 530347 | Eur J Med Chem. 2009 Dec;44(12):4862-88. Epub 2009 Aug 6.Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. | ||||
Ref 530367 | Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. | ||||
Ref 530368 | Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. Epub 2009 Aug 20.Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents fordepression. | ||||
Ref 530442 | J Med Chem. 2009 Nov 12;52(21):6768-81.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. | ||||
Ref 530455 | Bioorg Med Chem. 2009 Nov 15;17(22):7802-15. Epub 2009 Sep 18.Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles. | ||||
Ref 530474 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. | ||||
Ref 530596 | Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. Epub 2009 Dec 6.Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agonists. | ||||
Ref 530728 | J Med Chem. 2010 Mar 11;53(5):2204-14.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. | ||||
Ref 530783 | Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81. | ||||
Ref 530914 | Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. Epub 2010 Apr 13.Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioamphetamines. | ||||
Ref 530918 | Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. Epub 2010 Apr 18.Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity. | ||||
Ref 530946 | J Med Chem. 2010 Jun 24;53(12):4731-48.Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. | ||||
Ref 531079 | J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. | ||||
Ref 531114 | Bioorg Med Chem Lett. 2010 Sep 15;20(18):5567-71. Epub 2010 Aug 17.Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. | ||||
Ref 532351 | Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6. | ||||
Ref 532361 | Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. | ||||
Ref 532685 | Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91. | ||||
Ref 533083 | Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. | ||||
Ref 533091 | Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. | ||||
Ref 533235 | Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. | ||||
Ref 533479 | J Med Chem. 1986 Aug;29(8):1406-12.Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-aminoethyl)-2,3-dihydroindoles. | ||||
Ref 534240 | J Med Chem. 1996 Oct 11;39(21):4139-41.3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine transporter. | ||||
Ref 534848 | Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83. | ||||
Ref 534900 | The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. | ||||
Ref 535127 | Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. | ||||
Ref 535503 | Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. | ||||
Ref 536025 | New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302. | ||||
Ref 536083 | Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28. | ||||
Ref 536122 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | ||||
Ref 536168 | Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. Epub 2006 Jan 4. | ||||
Ref 536286 | Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. | ||||
Ref 536331 | Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. | ||||
Ref 536499 | Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. | ||||
Ref 536580 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
Ref 536749 | Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. Epub 2008 Jun 22. | ||||
Ref 536774 | Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. | ||||
Ref 536967 | Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. Epub 2008 Nov 30. | ||||
Ref 537241 | Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. Epub 2009 Apr 17. | ||||
Ref 537422 | Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. | ||||
Ref 537457 | Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Jun 11. | ||||
Ref 537531 | Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31. Epub 2009 Apr 8. | ||||
Ref 537742 | Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55. | ||||
Ref 537875 | Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. | ||||
Ref 537983 | A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90. | ||||
Ref 543974 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). | ||||
Ref 549028 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) | ||||
Ref 551382 | The origin of <span class="caps">MDMA</span> (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.